PMID- 27260129
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20220316
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 22
DP  - 2016 Jun 4
TI  - A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine 
      Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic 
      Hyperplasia.
PG  - 1895-902
AB  - BACKGROUND Benign prostatic hyperplasia (BPH), a common disease in men over age 
      50 years, often causes bladder outlet obstruction and lower urinary tract 
      symptoms (LUTS). Alpha blockers in combination with muscarinic receptor 
      antagonists may have the potential to improve symptoms. This study aimed to 
      assess the efficacy and safety of doxazosin or tamsulosin combined with 
      tolterodine extend release (ER) in patients with BPH and LUTS. MATERIAL AND 
      METHODS In a prospective, randomized, open-label study (ChiCTR-IPR-15005763), 220 
      consecutive men with BPH and LUTS were allocated to receive doxazosin 4 mg and 
      tolterodine ER 4 mg per day (doxazosin group) or tamsulosin 0.2 mg and 
      tolterodine ER 4 mg per day (tamsulosin group). Treatment lasted 12 weeks. The 
      primary endpoint was the international prostatic symptom score (IPSS). Secondary 
      endpoints were quality of life (QoL) and maximum flow rate (Qmax), which were 
      evaluated at 0, 6, and 12 weeks, and urodynamic parameters assessed at 0 and 12 
      weeks. RESULTS A total of 192 patients completed the trial. Baseline measurements 
      showed no differences between the groups. After 6 weeks, IPSS improved in both 
      groups and QoL was significantly better in the doxazosin group (P=0.01). After 12 
      weeks, Qmax, IPSS, QoL, intravesical pressure (Pves), and bladder compliance (BC) 
      in the doxazosin group were significantly better than in the tamsulosin group 
      (P=0.03, P<0.001, P<0.001, P=0.027, and P=0.044, respectively). CONCLUSIONS 
      Administration of alpha blockers combined with muscarinic receptor blocker for 12 
      weeks improved LUTS in men with BPH.
FAU - Cao, Yanwei
AU  - Cao Y
AD  - Department of Urology, Qingdao University Affiliated Hospital, Qingdao, Shandong, 
      China (mainland).
FAU - Wang, Yonghua
AU  - Wang Y
AD  - Department of Urology, Qingdao University Affiliated Hospital, Qingdao, Shandong, 
      China (mainland).
FAU - Guo, Lei
AU  - Guo L
AD  - Department of Urology, Qingdao University Affiliated Hospital, Qingdao, Shandong, 
      China (mainland).
FAU - Yang, Xuecheng
AU  - Yang X
AD  - Department of Urology, Qingdao University Affiliated Hospital, Qingdao, Shandong, 
      China (mainland).
FAU - Chen, Tao
AU  - Chen T
AD  - Department of Urology, Qingdao University Affiliated Hospital, Qingdao, Shandong, 
      China (mainland).
FAU - Niu, Haitao
AU  - Niu H
AD  - Department of Urology, Qingdao University Affiliated Hospital, Qingdao, Shandong, 
      China (mainland).
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160604
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Sulfonamides)
RN  - 5T619TQR3R (Tolterodine Tartrate)
RN  - G3P28OML5I (Tamsulosin)
RN  - NW1291F1W8 (Doxazosin)
SB  - IM
MH  - Adrenergic alpha-Antagonists/therapeutic use
MH  - Aged
MH  - Doxazosin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Quality of Life
MH  - Sulfonamides/*therapeutic use
MH  - Tamsulosin
MH  - Tolterodine Tartrate/*therapeutic use
PMC - PMC4917326
EDAT- 2016/06/05 06:00
MHDA- 2017/03/04 06:00
PMCR- 2016/06/04
CRDT- 2016/06/05 06:00
PHST- 2016/06/05 06:00 [entrez]
PHST- 2016/06/05 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
PHST- 2016/06/04 00:00 [pmc-release]
AID - 896283 [pii]
AID - 10.12659/msm.896283 [doi]
PST - epublish
SO  - Med Sci Monit. 2016 Jun 4;22:1895-902. doi: 10.12659/msm.896283.